Virchows Archiv

, Volume 458, Issue 4, pp 453–465

Gene expression profiling of human hepatoblastoma using archived formalin-fixed and paraffin-embedded tissues

  • Eun Shin
  • Kyoung-Bun Lee
  • Soo-Young Park
  • Soo-Hee Kim
  • Han-Suk Ryu
  • Young-Nyun Park
  • Eunsil Yu
  • Ja-June Jang
Original Article

Abstract

We elucidated the genetic profile of hepatoblastomas (HBLs) to identify diagnostic and prognostic markers. RNA was extracted from 32 formalin-fixed, paraffin-embedded HBLs and corresponding nonneoplastic liver (NNL) tissues, and cDNA-mediated annealing, selection, extension, and ligation (DASL) chip assays were performed. Immunohistochemistry was performed to confirm the expression of Yin Yang 1 (YY1) protein in HBL. Twenty-four genes that were associated with signal transduction, cell–cell adhesion, cell cycle regulation, and apoptosis were differentially expressed in HBL and NNL tissues. Two apoptosis-associated genes, MYCN and BIRC5, were highly upregulated in HBL. Eight genes, including YY1 and IGF1, were upregulated in HBL cases that had a poor prognosis. Thirty-eight genes, including YY1, were differentially expressed according to histologic differentiation of HBL, and the immunohistochemical expression of YY1 was correlated with poor HBL differentiation. Thus, using DASL chip assays, we report the gene expression profiles of HBL, which suggest new candidate prognostic and diagnostic genetic markers and putative therapeutic targets for HBL.

Keywords

Hepatoblastoma DASL chip assay YY1 Prognosis 

References

  1. 1.
    Roebuck DJ, Perilongo G (2006) Hepatoblastoma: an oncological review. Pediatr Radiol 36:183–186PubMedCrossRefGoogle Scholar
  2. 2.
    Schnater JM, Kohler SE, Lamers WH, von Schweinitz D, Aronson DC (2003) Where do we stand with hepatoblastoma? A review. Cancer 98:668–678PubMedCrossRefGoogle Scholar
  3. 3.
    Hu J, Wills M, Baker BA, Perlman EJ (2000) Comparative genomic hybridization analysis of hepatoblastomas. Genes Chromosom Cancer 27:196–201PubMedCrossRefGoogle Scholar
  4. 4.
    Weber RG, Pietsch T, von Schweinitz D, Lichter P (2000) Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol 157:571–578PubMedCrossRefGoogle Scholar
  5. 5.
    Curia MC, Zuckermann M, De Lellis L, Catalano T, Lattanzio R, Aceto G, Veschi S, Cama A, Otte JB, Piantelli M, Mariani-Costantini R, Cetta F, Battista P (2008) Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations. Mod Pathol 21:7–14PubMedCrossRefGoogle Scholar
  6. 6.
    Jeng YM, Wu MZ, Mao TL, Chang MH, Hsu HC (2000) Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett 152:45–51PubMedCrossRefGoogle Scholar
  7. 7.
    Akmal SN, Yun K, MacLay J, Higami Y, Ikeda T (1995) Insulin-like growth factor 2 and insulin-like growth factor binding protein 2 expression in hepatoblastoma. Hum Pathol 26:846–851PubMedCrossRefGoogle Scholar
  8. 8.
    Gray SG, Eriksson T, Ekstrom C, Holm S, von Schweinitz D, Kogner P, Sandstedt B, Pietsch T, Ekstrom TJ (2000) Altered expression of members of the IGF-axis in hepatoblastomas. Br J Cancer 82:1561–1567PubMedCrossRefGoogle Scholar
  9. 9.
    Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531–537PubMedCrossRefGoogle Scholar
  10. 10.
    Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRefGoogle Scholar
  11. 11.
    Boyer J, Allen WL, McLean EG, Wilson PM, McCulla A, Moore S, Longley DB, Caldas C, Johnston PG (2006) Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 66:2765–2777PubMedCrossRefGoogle Scholar
  12. 12.
    Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412:822–826PubMedCrossRefGoogle Scholar
  13. 13.
    Nagata T, Takahashi Y, Ishii Y, Asai S, Nishida Y, Murata A, Koshinaga T, Fukuzawa M, Hamazaki M, Asami K, Ito E, Ikeda H, Takamatsu H, Koike K, Kikuta A, Kuroiwa M, Watanabe A, Kosaka Y, Fujita H, Miyake M, Mugishima H (2003) Transcriptional profiling in hepatoblastomas using high-density oligonucleotide DNA array. Cancer Genet Cytogenet 145:152–160PubMedCrossRefGoogle Scholar
  14. 14.
    Luo JH, Ren B, Keryanov S, Tseng GC, Rao UN, Monga SP, Strom S, Demetris AJ, Nalesnik M, Yu YP, Ranganathan S, Michalopoulos GK (2006) Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 44:1012–1024PubMedCrossRefGoogle Scholar
  15. 15.
    Yamada S, Ohira M, Horie H, Ando K, Takayasu H, Suzuki Y, Sugano S, Hirata T, Goto T, Matsunaga T, Hiyama E, Hayashi Y, Ando H, Suita S, Kaneko M, Sasaki F, Hashizume K, Ohnuma N, Nakagawara A (2004) Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 23:5901–5911PubMedCrossRefGoogle Scholar
  16. 16.
    Bibikova M, Talantov D, Chudin E, Yeakley JM, Chen J, Doucet D, Wickham E, Atkins D, Barker D, Chee M, Wang Y, Fan JB (2004) Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol 165:1799–1807PubMedCrossRefGoogle Scholar
  17. 17.
    Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359:1995–2004PubMedCrossRefGoogle Scholar
  18. 18.
    Fan JB, Yeakley JM, Bibikova M, Chudin E, Wickham E, Chen J, Doucet D, Rigault P, Zhang B, Shen R, McBride C, Li HR, Fu XD, Oliphant A, Barker DL, Chee MS (2004) A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res 14:878–885PubMedCrossRefGoogle Scholar
  19. 19.
    Fan JB, Oliphant A, Shen R, Kermani BG, Garcia F, Gunderson KL, Hansen M, Steemers F, Butler SL, Deloukas P, Galver L, Hunt S, McBride C, Bibikova M, Rubano T, Chen J, Wickham E, Doucet D, Chang W, Campbell D, Zhang B, Kruglyak S, Bentley D, Haas J, Rigault P, Zhou L, Stuelpnagel J, Chee MS (2003) Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol 68:69–78PubMedCrossRefGoogle Scholar
  20. 20.
    Schwab M (2004) MYCN in neuronal tumours. Cancer Lett 204:179–187PubMedCrossRefGoogle Scholar
  21. 21.
    Mertens F, Mandahl N, Mitelman F, Heim S (1994) Cytogenetic analysis in the examination of solid tumors in children. Pediatr Hematol Oncol 11:361–377PubMedCrossRefGoogle Scholar
  22. 22.
    Morgenstern DA, Anderson J (2006) MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma. Expert Rev Anticancer Ther 6:217–224PubMedCrossRefGoogle Scholar
  23. 23.
    Tsuda H, Shimosato Y, Upton MP, Yokota J, Terada M, Ohira M, Sugimura T, Hirohashi S (1988) Retrospective study on amplification of N-myc and c-myc genes in pediatric solid tumors and its association with prognosis and tumor differentiation. Lab Invest 59:321–327PubMedGoogle Scholar
  24. 24.
    Mares J, Polanska V, Gorgens H, Sedlacek Z, Marikova T, Bocek P, Kodet R, Schackert J, Goetz P (1998) Oncogene amplification and expression in pediatric solid tumors. Neoplasma 45:123–127PubMedGoogle Scholar
  25. 25.
    Fest S, Huebener N, Bleeke M, Durmus T, Stermann A, Woehler A, Baykan B, Zenclussen AC, Michalsky E, Jaeger IS, Preissner R, Hohn O, Weixler S, Gaedicke G, Lode HN (2009) Survivin minigene DNA vaccination is effective against neuroblastoma. Int J Cancer 125:104–114PubMedCrossRefGoogle Scholar
  26. 26.
    Eckerle I, Muth D, Batzler J, Henrich KO, Lutz W, Fischer M, Witt O, Schwab M, Westermann F (2009) Regulation of BIRC5 and its isoform BIRC5-2B in neuroblastoma. Cancer Lett 285:99–107PubMedCrossRefGoogle Scholar
  27. 27.
    Yoshida R, Ogata T, Masawa N, Nagai T (2008) Hepatoblastoma in a Noonan syndrome patient with a PTPN11 mutation. Pediatr Blood Cancer 50:1274–1276PubMedCrossRefGoogle Scholar
  28. 28.
    Adesina AM, Lopez-Terrada D, Wong KK, Gunaratne P, Nguyen Y, Pulliam J, Margolin J, Finegold MJ (2009) Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol 40:843–853PubMedCrossRefGoogle Scholar
  29. 29.
    LeRoith D, Roberts CT Jr (2003) The insulin-like growth factor system and cancer. Cancer Lett 195:127–137PubMedGoogle Scholar
  30. 30.
    Braconi C, Bracci R, Bearzi I, Bianchi F, Sabato S, Mandolesi A, Belvederesi L, Cascinu S, Valeri N, Cellerino R (2008) Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol 19:1293–1298PubMedCrossRefGoogle Scholar
  31. 31.
    Gordon S, Akopyan G, Garban H, Bonavida B (2006) Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 25:1125–1142PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Eun Shin
    • 1
  • Kyoung-Bun Lee
    • 1
  • Soo-Young Park
    • 1
  • Soo-Hee Kim
    • 1
  • Han-Suk Ryu
    • 1
  • Young-Nyun Park
    • 2
  • Eunsil Yu
    • 3
  • Ja-June Jang
    • 1
  1. 1.Department of PathologySeoul National University College of MedicineSeoulSouth Korea
  2. 2.Department of PathologyYonsei University College of MedicineSeoulSouth Korea
  3. 3.Department of PathologySeoul Asan Medical CenterSeoulSouth Korea

Personalised recommendations